The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_1C589D62C589
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.
Journal
Proceedings of the National Academy of Sciences of the United States of America
Author(s)
Manry J., Bastard P., Gervais A., Le Voyer T., Rosain J., Philippot Q., Michailidis E., Hoffmann H.H., Eto S., Garcia-Prat M., Bizien L., Parra-Martínez A., Yang R., Haljasmägi L., Migaud M., Särekannu K., Maslovskaja J., de Prost N., Tandjaoui-Lambiotte Y., Luyt C.E., Amador-Borrero B., Gaudet A., Poissy J., Morel P., Richard P., Cognasse F., Troya J., Trouillet-Assant S., Belot A., Saker K., Garçon P., Rivière J.G., Lagier J.C., Gentile S., Rosen L.B., Shaw E., Morio T., Tanaka J., Dalmau D., Tharaux P.L., Sene D., Stepanian A., Mégarbane B., Triantafyllia V., Fekkar A., Heath J.R., Franco J.L., Anaya J.M., Solé-Violán J., Imberti L., Biondi A., Bonfanti P., Castagnoli R., Delmonte O.M., Zhang Y., Snow A.L., Holland S.M., Biggs C.M., Moncada-Vélez M., Arias A.A., Lorenzo L., Boucherit S., Anglicheau D., Planas A.M., Haerynck F., Duvlis S., Ozcelik T., Keles S., Bousfiha A.A., El Bakkouri J., Ramirez-Santana C., Paul S., Pan-Hammarström Q., Hammarström L., Dupont A., Kurolap A., Metz C.N., Aiuti A., Casari G., Lampasona V., Ciceri F., Barreiros L.A., Dominguez-Garrido E., Vidigal M., Zatz M., van de Beek D., Sahanic S., Tancevski I., Stepanovskyy Y., Boyarchuk O., Nukui Y., Tsumura M., Vidaur L., Tangye S.G., Burrel S., Duffy D., Quintana-Murci L., Klocperk A., Kann N.Y., Shcherbina A., Lau Y.L., Leung D., Coulongeat M., Marlet J., Koning R., Reyes L.F., Chauvineau-Grenier A., Venet F., Monneret G., Nussenzweig M.C., Arrestier R., Boudhabhay I., Baris-Feldman H., Hagin D., Wauters J., Meyts I., Dyer A.H., Kennelly S.P., Bourke N.M., Halwani R., Sharif-Askari F.S., Dorgham K., Sallette J., Sedkaoui S.M., AlKhater S., Rigo-Bonnin R., Morandeira F., Roussel L., Vinh D.C., Erikstrup C., Condino-Neto A., Prando C., Bondarenko A., Spaan A.N., Gilardin L., Fellay J., Lyonnet S., Bilguvar K., Lifton R.P., Mane S., Anderson M.S., Boisson B., Béziat V., Zhang S.Y., Andreakos E., Hermine O., Pujol A., Peterson P., Mogensen T.H., Rowen L., Mond J., Debette S., de Lamballerie X., Burdet C., Bouadma L., Zins M., Soler-Palacin P., Colobran R., Gorochov G., Solanich X., Susen S., Martinez-Picado J., Raoult D., Vasse M., Gregersen P.K., Piemonti L., Rodríguez-Gallego C., Notarangelo L.D., Su H.C., Kisand K., Okada S., Puel A., Jouanguy E., Rice C.M., Tiberghien P., Zhang Q., Casanova J.L., Abel L., Cobat A.
Working group(s)
HGID Lab, COVID Clinicians, COVID-STORM Clinicians, NIAID Immune Response to COVID Group, NH-COVAIR Study Group, Danish CHGE, Danish Blood Donor Study, St. James's Hospital, SARS CoV2 Interest Group, French COVID Cohort Study Group, Imagine COVID-Group, Milieu Intérieur Consortium, CoV-Contact Cohort, Amsterdam UMC Covid-19 Biobank Investigators, COVID Human Genetic Effort, CP-COVID-19 Group, CONSTANCES cohort, 3C-Dijon Study, Cerba Health-Care, Etablissement Français du Sang Study group
ISSN
1091-6490 (Electronic)
ISSN-L
0027-8424
Publication state
Published
Issued date
24/05/2022
Peer-reviewed
Oui
Volume
119
Number
21
Pages
e2200413119
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR) doubles with every 5 y of age from childhood onward. Circulating autoantibodies neutralizing IFN-α, IFN-ω, and/or IFN-β are found in ∼20% of deceased patients across age groups, and in ∼1% of individuals aged <70 y and in >4% of those >70 y old in the general population. With a sample of 1,261 unvaccinated deceased patients and 34,159 individuals of the general population sampled before the pandemic, we estimated both IFR and relative risk of death (RRD) across age groups for individuals carrying autoantibodies neutralizing type I IFNs, relative to noncarriers. The RRD associated with any combination of autoantibodies was higher in subjects under 70 y old. For autoantibodies neutralizing IFN-α2 or IFN-ω, the RRDs were 17.0 (95% CI: 11.7 to 24.7) and 5.8 (4.5 to 7.4) for individuals <70 y and ≥70 y old, respectively, whereas, for autoantibodies neutralizing both molecules, the RRDs were 188.3 (44.8 to 774.4) and 7.2 (5.0 to 10.3), respectively. In contrast, IFRs increased with age, ranging from 0.17% (0.12 to 0.31) for individuals <40 y old to 26.7% (20.3 to 35.2) for those ≥80 y old for autoantibodies neutralizing IFN-α2 or IFN-ω, and from 0.84% (0.31 to 8.28) to 40.5% (27.82 to 61.20) for autoantibodies neutralizing both. Autoantibodies against type I IFNs increase IFRs, and are associated with high RRDs, especially when neutralizing both IFN-α2 and IFN-ω. Remarkably, IFRs increase with age, whereas RRDs decrease with age. Autoimmunity to type I IFNs is a strong and common predictor of COVID-19 death.
Keywords
Adult, Age Factors, Aged, Aged, 80 and over, Antibodies, Neutralizing/blood, Autoantibodies/blood, Autoimmunity, COVID-19/immunology, COVID-19/mortality, Female, Humans, Interferon Type I/immunology, Male, Middle Aged, Risk, SARS-CoV-2, COVID-19, autoantibodies, infection fatality rate, relative risk, type I IFNs
Pubmed
Create date
31/05/2022 13:07
Last modification date
23/11/2022 6:50
Usage data